Daniel W Pierce

USPTO Granted Patents = 11 (Patent Applications = 9)

EPO Patents = 3 (Patent Applications = 8)

Average Co-Inventor Count = 4.2

ph-index = 5

Forward Citations = 45(Granted Patents)

Company Filing History:

Abraxis Bioscience, LLC

patents

Years Active: 2019-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12090147 - Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide (2024-09-17),

2. 12061183 - Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug (2024-08-13),

3. 12053466 - Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use (2024-08-06),

4. 12029738 - Antiproliferative compounds and methods of use thereof (2024-07-09),

5. 11439637 - Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use (2022-09-13),

6. 11320416 - Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug (2022-05-03),

7. 11185543 - Antiproliferative compounds and methods of use thereof (2021-11-30),

8. 10900951 - Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel (2021-01-26),

9. 10705070 - Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug (2020-07-07),

10. 10527604 - Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel (2020-01-07),

11. 10357489 - Antiproliferative compounds and methods of use thereof (2019-07-23),

Title: Daniel W. Pierce: Innovator in Pharmaceutical Sciences

Introduction

Daniel W. Pierce, an accomplished inventor based in Belmont, California, holds a remarkable portfolio of 11 patents. His contributions to the field of pharmaceutical sciences have paved the way for innovative therapies, particularly in treating conditions associated with cancer.

Latest Patents

Among his latest inventions, Pierce has developed a patented method for treating, preventing, managing, and ameliorating hypotension linked to the administration of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide. The methods emphasize the use of a combination therapy that includes this compound along with glucocorticoid receptor agonists or interleukin-1 receptor antagonists, targeting optimal treatment for cancer patients. Additionally, he has created innovative methods for assessing the suitability of pharmaceutical compositions that feature nanoparticles comprising rapamycin coated with albumin.

Career Highlights

Throughout his career, Daniel W. Pierce has made significant strides while working for renowned companies such as Celgene Corporation and Abraxis Bioscience, LLC. His experience in these organizations has greatly influenced his innovative spirit and patent-driven endeavors, focusing on improving health outcomes through scientific advancements.

Collaborations

Collaboration has been an essential aspect of Pierce's journey. He has worked alongside notable individuals like Lilly L. Wong and Viktor Peykov, fostering a dynamic exchange of ideas that enhances the field of biomedical innovation.

Conclusion

Daniel W. Pierce stands out as a remarkable inventor in the pharmaceutical industry, contributing substantially through his patents and collaborative efforts. His work continues to impact the development of novel therapies, showcasing the importance of innovation in improving patient care and outcomes.

This text is generated by artificial intelligence and may not be accurate.